Afecta Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Afecta Pharmaceuticals Inc. is using its pharmacogenetic platform to match complex forms of neurologic and psychiatric illnesses with the chemistry of candidate drugs that can be rapidly developed for treating the illnesses. Afecta intends to identify compounds to serve unmet clinical needs and to partner with others to bring targeted compounds to market at significantly lower R&D cost than de novo discovery.